Full-Time

Medical Science Liaison

Posted on 5/16/2026

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

No salary listed

Washington, DC, USA

In Person

Category
Biology & Biotech (1)
Requirements
  • Advanced scientific degree (MD, OD, PhD, PharmD) or clinical degree (Nurse Practitioner, Physician Assistant); or equivalent clinical experience (e.g., Registered Nurse, Radiologic Technologist) if appropriate
  • 2+ years’ experience in the pharmaceutical industry, other healthcare environment or equivalent experience
  • Ability to effectively communicate scientific content through face-to-face individual meetings, small group interactions, and in writing
  • Effective collaboration with internal departments is essential, and the ability to work cohesively as a strong team player
  • Demonstrate independence, adaptability, and strong interpersonal skills while showcasing problem-solving abilities, strategic thinking, and a patient-centered approach
  • Be committed to full compliance with all company Standard Operating Procedures, regulatory requirements, and applicable laws including Pharmaceutical Research and Manufacturers of America guidelines for field-based personnel.
  • Must possess a valid driver’s license
Responsibilities
  • Develop relationships with focus Key Opinion Leaders in their assigned territory through engaging in scientific exchange
  • Engage in peer-to-peer scientific dialogue effectively communicating scientific, medical, technical, or product (reactive) content
  • Support Healthcare Professional field education, training, and safe use of drugs or biologics
  • Assess KOL alignment with the key scientific discussion topics to inform territory and medical strategy
  • Identify KOL Advocates and Collaborators within your assigned territory
  • Compliantly support company sponsored research, investigator-initiated research, external collaborative research, and publications associated with Keenova Therapeutics product(s)
  • Stay abreast of emerging scientific literature/clinical data and translate to applicable knowledge
  • Ensure appropriate communication of clinical and scientific information regarding FDA approved and pipeline products in a timely, ethical, and customer-focused manner with support of your manager
  • Respond to Medical Information Requests within the specified timelines (initial contact within 2 days and full answer within 3 weeks) when a standard response letter does not exist
  • Collect scientific and clinical insights based on scientific information/clinical data sharing to optimize medical communications and coordinated strategy and tactics across the organization
  • Respond to all requests for directed insights within the expected timeframe
  • Participate in advisory boards as requested
  • Contributes scientific content and/or helps create materials in support of a project or initiative
  • Participate in team calls, projects, and activities
  • Collaborate with MSL colleagues
  • Understand and operate in alignment with the Keenova Therapeutics Values and Leadership Framework
Desired Qualifications
  • Prior experience in Hepatology, Nephrology, or Transplantation
  • Demonstrated ability to access and develop relationships with external stakeholders
  • Thorough knowledge of medicine, treatment guidelines, clinical research processes, customer strategies, and FDA promotional guidelines, regulations, and ethical guidelines

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Mallinckrodt who can refer or advise you

Benefits

Performance Bonus

Relocation Assistance

Company News

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.